Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Thursday 22 December, 2011

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 5265U
GlaxoSmithKline PLC
22 December 2011
 



This announcement amends the original announcements released on 12 April 2011 at 18.00 (RNS No: 7966E); 12 July 2011 at 17.33 (RNS No: 2743K); and 11 October 2011 at 16.54 (RNS No: 9956P)

 

The Administrators of the GlaxoSmithKline Performance Share Plan (the "Plan") notified the Company and the under-mentioned persons on 21 December 2011 of an error in the market price of Ordinary shares which was used to calculate the notional number of shares received under the dividend reinvestment element of the Plan, in respect of dividends paid on 7 April 2011. The market price of Ordinary shares should have read 1216.50 pence rather than £12.22, and the participants' increased interests in Ordinary shares have been amended and the correct interests are set out below.

 

Given the cumulative nature of the dividend reinvestment, the correction in respect of the payment made on 7 April 2011 also had a minor impact on the calculation of the dividends reinvested for the affected Plan participants in respect of the dividend payments made on 7 July 2011 and 6 October 2011.

 

Amendments are identified with an asterisk (*).

 

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

 

 

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

 

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 12 April 2011 of an increase in their notional interests in Ordinary shares at a price of 1216.50 pence* per share and ADRs at a price of $39.96 per ADR following the notional re-investment of the dividend paid to shareholders on 7 April 2011.

 

 


Ordinary shares

ADRs

Mr A P Witty

14,654.300*


Dr M M Slaoui


3,232.51

Mr S M Bicknell

1,100.996*


Mr J M Clarke

3,315.717*


Mrs D P Connelly


2,284.17

Mr M Dunoyer

1,585.952*


Mr E J Gray

2,387.414*


Mr S A Hussain

3,280.149*


Mr W C Louv


997.91

Dr D Pulman


1,589.94

Mr D S Redfern

1,331.022*


Mr J R Stéphenne

1,976.996*


Ms C Thomas

1,958.903*


Mr D E Troy


2,071.71

Dr P J T Vallance

1,219.257*


Mrs V A Whyte

101.106*


 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

 

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).

 

V A Whyte

Company Secretary

 

12 April 2011

 

 

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

 

 

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 12 July 2011 of an increase in their notional interests in Ordinary shares at a price of 1366.50 pence per Ordinary share and ADRs at a price of $43.91 per ADR following the notional re-investment of the dividend paid to shareholders on 7 July 2011.

 

 


Ordinary shares

ADRs

Mr A P Witty

16,127.194*


Dr M M Slaoui


      4,323.445

Mr S M Bicknell

1,434.634*


Mr J M Clarke

4,015.431*


Mrs D P Connelly


2,544.286

Mr M Dunoyer

1,887.492*


Mr E J Gray

3,030.337*


Mr S A Hussain

3,962.111*


Mr W C Louv


1,304.354

Dr D Pulman


1,954.980

Mr D S Redfern

1,848.325*


Mr J R Stéphenne

2,322.380*


Ms C Thomas

2,664.317*


Mr P C Thomson

215.143*


Mr D E Troy


2,580.684

Dr P J T Vallance

2,618.026*


Ms E Walmsley

1,557.625*


Mrs V A Whyte

215.143*


 

 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

 

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).

 

 

V A Whyte

Company Secretary

 

12 July 2011

 

 

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

 

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 11 October 2011 of an increase in their notional interests in Ordinary shares at a price of 1365 pence per Ordinary share and ADRs at a price of $42.37 per ADR following the notional re-investment of the dividend paid to shareholders on 6 October 2011.

 

 


Ordinary shares

ADRs

Mr A P Witty

16,333.952*


Dr M M Slaoui


      4,489.084

Mr S M Bicknell

1,453.027*


Mr J M Clarke

4,066.911*


Mrs D P Connelly


2,641.762

Mr M Dunoyer

1,911.691*


Mr E J Gray

3,069.188*


Mr S A Hussain

4,012.908*


Mr W C Louv


1,354.326

Dr D Pulman


2,029.879

Mr D S Redfern

1,872.021*


Mr J R Stéphenne

2,352.155*


Ms C Thomas

2,698.475*


Mr P C Thomson

217.901*


Mr D E Troy


2,679.555

Dr P J T Vallance

2,651.590*


Ms E Walmsley

1,577.595*


Mrs V A Whyte

217.901*


 

 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

 

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

 

V A Whyte

Company Secretary

 

11 October 2011


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSZLLFLFLFEFBD

a d v e r t i s e m e n t